Latest news with #T1D
Newsweek
2 days ago
- Politics
- Newsweek
Susan Collins Dealt New Polling Blow Ahead of 2026 Midterms
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Republican U.S. Senator Susan Collins of Maine was dealt a polling blow ahead of her potential reelection bid as the 2026 midterms approach, with Democrats hoping to unseat her in the Pine Tree State. Why It Matters Collins has continued gaining reelection despite Maine supporting Democrats in presidential elections since 1992, partly due to her moderate voting record. But Democrats are hoping a strong national push and diminishing approval from constituents during President Donald Trump's second administration could make her vulnerable next year. Whether Collins can retain support among independents and moderate Democrats will have key implications for whether she will be reelected next year. What To Know Morning Consult released its quarterly poll of senators' approval ratings this week and found that Collins is among four with negative scores. Only 38 percent of Mainers approve of her job performance, according to the pollster, which noted it is a "record low" for Collins. Meanwhile, 54 percent disapprove of her performance—a high point in the survey's history, spanning to 2017. That marks a notable decline from the fourth quarter of 2024, when 47 percent of Mainers approved of Collins and 44 percent disapproved, according to Morning Consult. In the third quarter of 2024, 50 percent of Mainers approved, and 42 percent disapproved of Collins. Republican U.S. Senator Susan Collins of Maine speaks in Washington, D.C., on June 4. Republican U.S. Senator Susan Collins of Maine speaks in Washington, D.C., on June Breakthrough T1D Morning Consult polls are based on a "three-month roll-up" of responses from daily tracking surveys among registered voters. Collins last won reelection in 2020 against Democrat Sara Gideon. At the time, most polls suggested Gideon had a lead, but Collins ultimately ended up winning with just over 50 percent of the vote. The only other senators with negative approval ratings in the poll were GOP Senators Joni Ernst of Iowa, Ron Johnson of Wisconsin and Mitch McConnell of Kentucky. Despite hopes of a blue wave, Democrats are facing a tough Senate map, making Collins' seat a must-win as they aim to regain control of Congress' upper chamber. In addition to Maine—which backed former Vice President Kamala Harris by about 7 percentage points—North Carolina, which Trump carried by about 3 percentage points, is viewed as Democrats' other top flip opportunity. Who Could Susan Collins Face in 2026 Midterms? On the Democratic side, two candidates have declared their intent to run. David Costello, who ran in 2024 and held several different positions in Maryland, including acting secretary of the state's Department of the Environment, is running again. Jordan Wood, who served as chief of staff to former Representative Katie Porter, a California Democrat, is also running. Governor Janet Mills has also not ruled out running. Some Democrats view her as their best chance of winning, as she has also won statewide by comfortable margins. Morning Consult's latest gubernatorial approval ratings, however, also delivered troubling news to Mills, though she was still narrowly above water with Mainers, scoring a +2 approval rating. "Janet Mills of Maine is term-limited as governor and viewed as one of the Democratic Party's best options to challenge moderate Republican Sen. Susan Collins in next year's midterm elections. But she's also the most unpopular Democratic governor in the country, and one of the only to lose popularity since the last quarter of 2024," the report reads. Collins has distanced herself from Trump, voting against his signature "One Big Beautiful Bill Act" over Medicaid cuts. She has long cast herself as the most moderate Republican in the Senate, which has helped her win elections. A Pan Atlantic Research Poll, which surveyed 840 likely Maine voters from May 12 to May 26, had better news for Collins. In that survey, 49 percent of respondents viewed her favorably, while only 45 percent viewed her unfavorably. A Collins spokesperson pointed to that poll when reached by Newsweek. Conversely, a University of New Hampshire poll released last month found that only 14 percent of Mainers view Collins favorably, while 57 percent view her unfavorably. An additional 26 percent were neutral. That poll surveyed 846 Maine residents from June 19 to June 23, and had a margin of error of plus or minus 3.4 percentage points. What People Are Saying Nick Puglia, regional press secretary for the National Republican Senatorial Committee, previously told Newsweek: "No one fights harder for Maine than Susan Collins, and she continues delivering big wins like protecting Social Security for over 25,000 Mainers and millions of Americans." Amy Walter, editor-in-chief of Cook Political Report, wrote on X: "For all the talk of Dem SEN opportunities in NC, TX and even IA, the red lights are really blaring in MAINE, where Morning Consult polling shows Trump underwater by 17 pts. SEN. Collins at -16. And yet NO serious Dem is taking the plunge to challenge her." What Happens Next Collins had not made a formal announcement about her reelection bid, but told CNN in May it is her "inclination to run" and that she is "preparing to do so." The Cook Political Report classifies the race as "Lean Republican," meaning it is "considered competitive," but that Collins "has an advantage." Sabato's Crystal Ball also classifies the race as leaning toward Republicans.
Business Wire
2 days ago
- Health
- Business Wire
Digostics Announces University Trial of New At-home Type 1 Diabetes Test Underway
OXFORD, England--(BUSINESS WIRE)--Researchers have initiated an evaluation of a new at-home test to diagnose and monitor early stages of type 1 diabetes (T1D), based on blood glucose levels. The test would be used in individuals who have already tested positive for T1D autoantibodies to identify where they may be in their early-stage T1D progression. The trial, which is funded by Breakthrough T1D (formerly JDRF) the leading global T1D research and advocacy organization, will assess the accuracy, reproducibility, and acceptability of the GTT@home Oral Glucose Tolerance Test (OGTT) compared to in-clinic OGTTs. The results of the trial will inform future regulatory submissions for GTT@home use in T1D, which already has regulatory approval in the UK, Europe and other regions for other types of diabetes. GTT@home is an OGTT developed by British diabetes home-testing company Digostics that uses finger-prick blood samples to measure how well the body processes glucose. The test, being studied at Yale School of Medicine in New Haven, Conn., has been shown to be as accurate as lab-based OGTTs when used in adults with glucose intolerance, type 2 diabetes, or in pregnant individuals to diagnosis gestational diabetes. The GTT@home test has successfully been implemented in several UK NHS Trusts to screen for gestational diabetes in pregnancy. Dr. Jennifer Sherr, Professor of Pediatric Endocrinology and the Medical Director of Pediatric Diabetes at Yale School of Medicine and co-lead principal investigator of the trial, said: 'As the presence of diabetes autoantibodies foretells an eventual diagnosis of T1D, it is critical to conduct an OGTT to stage the disease, which helps predict the risk of progression over time. Yet, in the current paradigm this requires coming to a clinical center or laboratory and getting venous blood draws. Despite knowing there is an increased risk of diabetes many individuals struggle to undergo an OGTT for staging, or repeat the test to permit ongoing monitoring. An at-home OGTT would alleviate this barrier. The ability to have those at risk use a product that is simple, requires fingerpricks instead of venous draws, and can be done within a person's own home at a date and time that is convenient for them would be a fantastic step forward for both patients and providers.' T1D can be diagnosed at any age, and it is the most common childhood autoimmune disease, affecting around one in 350 children. In T1D the body's immune system attacks and destroys the insulin-producing cells in the pancreas, resulting in elevated blood glucose levels. It affects every aspect of health and well-being and results in lifelong insulin dependence and an increased risk of major health problems such as heart disease, blindness, and kidney failure. In 40% or more of children the diagnosis of T1D is not made until the child has become severely unwell and presents with metabolic decompensation, which is known as diabetic ketoacidosis (DKA), a life-threatening diabetes complication. Dr. Raquel Lopez-Diez, Scientist at Breakthrough T1D commented, 'Breakthrough T1D is excited to fund this important work with Yale University School of Medicine to explore an at-home alternative to OGTT for glycemic monitoring in the early stages of type 1 diabetes. Traditional in-clinic OGTTs are time-consuming, can be challenging to navigate for younger individuals, and require significant clinic resources. As new therapies emerge that can delay and, hopefully, one day prevent the progression of type 1 diabetes, it is critical to have the tools to accurately and reliably monitor and diagnose the early stages of the disease. A validated at-home testing approach would represent a major breakthrough. We look forward to seeing the results of this important study.' T1D develops in stages over time, and early stages can be detected through a simple blood test. In stage 1 the body develops islet autoantibodies but the blood glucose levels are still normal. In stage 2, islet autoantibodies are present and individuals experience abnormal blood glucose or dysglycemia, and by stage 3 an individual has the clinical diagnosis of T1D and symptoms may begin to appear due to significant loss of insulin-producing cells. The OGTT is the gold-standard test recommended for defining the stage of T1D a person is experiencing, and it is the most sensitive test for monitoring T1D stages 1 and 2. Hospital-based OGTTs are often not well tolerated because they require placement of an intravenous line inserted into the vein or multiple blood draws, as several blood samples taken over 2-hours in a healthcare setting. Study lead Dr. Alfonso Galderisi, Associate Professor of Pediatrics at Yale School of Medicine, confirmed that the study will recruit 60 patients aged eight and over. 'To understand the ease of conducting the test, participants will complete an unsupervised GTT@home test. Five to seven days later, participants will come to our research unit and we will conduct the standard of care OGTT alongside a supervised GTT@home, with the results of the two tests compared to assess accuracy. We will also be interviewing participants to assess their perception of the two methods used to conduct OGTTs.' Glucose tolerance tests are performed in the morning after an overnight fast. The GTT@home test kit contains the test device, finger prickers for blood sample collection, a preformulated glucose drink, and detailed instructions. The process begins with an initial finger prick blood sample, followed by the consumption of the glucose drink. Two hours later, a second blood sample is taken. With standard clinic-based OGTTs, individuals need to travel to a clinic early in the morning and then undergo the two blood draws two hours apart and have an IV inserted. The GTT@home device analyses blood samples shortly after completion of the test and shares results in a timely manner directly with the study teams or clinician. Expedited analysis of samples eliminates the risk of sample degradation that can affect hospital-based OGTTs when samples are not sent to the lab immediately, improving diagnostic reliability. "The support from Breakthrough T1D and the team at Yale School of Medicine underscores once again the huge potential for our at-home OGTT for use in T1D," said James Jackson, CEO and Founder of Digostics. "We are working closely with the Yale study team to support this trial.'
TimesLIVE
3 days ago
- Entertainment
- TimesLIVE
‘Being different is cool': Lila Moss on becoming first Barbie with diabetes
Arzón debuted the new diabetes Barbie at Peloton Studios New York on July 8, where members of the T1D community gathered for the unveiling. 'After being diagnosed with type 1 diabetes a decade ago, I've found a lot of purpose in advocating for people with the condition. It's an honour to receive a Barbie doll as a part of the brand's efforts to grow awareness and representation. All types of challenges give us all the more reason to push forward and achieve our dreams,' said Arzón. Mattel said the new doll joins the Barbie Fashionistas line, which includes more than 175 diverse looks across varying skin tones, body types, hair textures and medical conditions, including Barbies with hearing aids, Down syndrome, vitiligo and a prosthetic limb. The 2025 Fashionistas range is also focused on sustainability. Mattel confirmed the new dolls commit to using at least 50% ISCC-certified bio-circular plastic, with packaging made from FSC-certified materials, which is part of the company's effort to reduce reliance on fossil-based materials. 'In 2020 Barbie kicked off a multi-year study with researchers at Cardiff University. It found doll play fosters empathy and social development, helping children imagine their futures on an equal playing field,' said Mattel. In South Africa 29-year-old singer Holly Rae was unveiled as a local ambassado alongside with 10-year-old dancer Sayuri Sewsunker. The 2025 Barbie Fashionistas line including the Type 1 Diabetes Barbie is available at the Mattel Shop and major retailers nationwide.
Yahoo
6 days ago
- Health
- Yahoo
Barbie just released a doll with diabetes. Here's why a B.C. content creator is calling it 'incredible'
Reviews and recommendations are unbiased and products are independently selected. Postmedia may earn an affiliate commission from purchases made through links on this page. When Bella Bucchiotti was 19, she was diagnosed with Type 1 diabetes (T1D). 'It came completely out of the blue, and adjusting to life with T1D was overwhelming,' the B.C.-based content creator and founder of the site recalls. 'There's no easing into it — one day you're fine, and the next you're figuring out insulin doses and how every bite of food might impact your blood sugar.' A chronic autoimmune disease that prevents your pancreas from making insulin, people with T1D require insulin therapies in order to survive. The diagnosis changed everything for Bucchiotti. Life, she says, became a constant balancing act. 'No one really sees all the mental load that comes with it,' Bucchiotti says. 'There's a huge learning curve, especially at the start — figuring out how your body responds to food, exercise, stress, even lack of sleep. Every day is different, and that can be exhausting.' Developing the tools and knowledge to help manage her diabetes, Bucchiotti says she's learned to live with Type 1, without letting it define her. Bucchiotti isn't alone in her diagnosis. According to the research and advocacy organization Breakthrough T1D, about 300,000 Canadians have T1D, with that number forecast to increase to 455,580 by 2040. Most diagnoses come between ages 10 and 14, according to Breakthrough T1D. But a diagnosis can come at any age. And that diagnosis can come as a shock. Looking to raise awareness about Type 1 diabetes, Mattel Inc. is releasing its first Barbie doll with the disease. The move, Bucchiotti says, could be helpful to people, especially young girls, who might be facing a T1D diagnosis. 'It's a way of being seen and not singled out,' she says. 'That really matters, especially in the beginning when you're learning how to manage it all and you feel so different from everyone around you.' As a new mother, Bucchiotti says the representation can impart an important message to children living with T1D: 'You're not broken, and you're not alone.' 'The mental-health side of diabetes is something we don't talk about enough, especially the isolation,' she says. 'A toy like this sends a message that living with Type 1 diabetes is just one part of who you are, and it doesn't have to make you feel like you don't belong.' Created in partnership with Breakthrough T1D, the new doll wears a continuous glucose monitor (CGM), an important tool that measures a person's blood-glucose level, held in place with a Barbie-pink piece of heart-shaped medical tape. 'Even now, seeing someone else with an insulin pump or CGM at the coffee shop makes me feel like I'm not alone,' Bucchiotti notes of the noticeable inclusion. 'That quiet connection is something really special, because no one else quite understands how tough some days can be.' The doll also features an insulin pump, a small device that allows for insulin dosing as needed, at the waist. 'It gives kids someone — even in doll-form — who truly reflects their experience,' Bucchiotti remarks of the realistic elements of the polka-dot-dress-wearing Barbie. 'Instead of feeling different or ashamed, they see something familiar, something that makes their condition feel normal. 'A Barbie with a CGM might seem like a small gesture, but for a child navigating a life-changing diagnosis, it can bring comfort, confidence and a sense of belonging. It can also open the door for conversations with friends and classmates, helping to build empathy and break down stigma.' Part of the Barbie Fashionistas' line, the Barbie doll with Type 1 joins a collection of more than 175 looks who feature a wide variety of skin tones, eye and hair colours, body types, ethnicities, disabilities and more. The latest doll reflects an 'important step' in Mattel Inc.'s commitment to inclusivity and representation, according to Krista Berger, senior vice-president of Barbie and global head of dolls. For Bucchiotti, the doll represents an important point of connection for the community of people around the world living with the disease. 'Type 1 diabetes is relentless, but it builds a kind of strength you don't expect,' she says. 'It's not always easy, but the T1D community is incredibly supportive. 'Sometimes it's a message from someone who's been there, or even just spotting a CGM on a stranger across the room — those small moments of connection remind you that you're not in this alone.' Aharris@ Opinion: Living with multiple sclerosis is difficult. Living in B.C. makes it harder Margot Robbie would like to make a Barbie musical
7NEWS
6 days ago
- Health
- 7NEWS
Sozo Australia: The Aussie haircare brand born from a shock diabetes diagnosis — now loved by thousands
Sozo Australia is a haircare brand with a founder who knows all too well the struggles of hair loss firsthand. From July 13 to 19, Australia observes National Diabetes Week, a time to raise awareness of one of the country's most misunderstood chronic illnesses. For Isabella Charanduk, Founder of Sozo Australia, this week carries a deeply personal significance. Her own experience with an unexpected and life-threatening diagnosis of Type 1 Diabetes (T1D) changed the course of her life and led to the creation of an all-natural haircare range that is now transforming lives. In 2019, Isabella found herself in the Intensive Care Unit (ICU), fighting for her life. She had developed Diabetic Ketoacidosis (DKA), which is a serious and potentially fatal complication that often accompanies the initial onset of T1D when left undiagnosed. For two months prior, she had been unknowingly living with tell-tale symptoms of the autoimmune condition, unaware that her body was in crisis. 'I was extremely unwell and didn't know how close I was to serious, irreversible harm,' Isabella tells Best Picks. 'The symptoms were there, but I didn't recognise them for what they were.' Isabella's message today is simple but urgent: know the warning signs. The symptoms she experienced fall into a group commonly referred to as the four Ts: Tired: Experiencing extreme or unexplained fatigue. Thirsty: Excessive and unquenchable thirst. Toilet: Frequent urination, even during the night. Thinner: Sudden, unexplained weight loss. Type 1 Diabetes can strike anyone at any age, often without warning, and its early signs are too often mistaken or ignored. Following her diagnosis and recovery, Isabella faced a new challenge: telogen effluvium, a temporary form of hair loss triggered by physical stress and illness. As she watched her hair thin and shed in alarming amounts, she began searching for solutions, but the products she found either contained harsh chemicals or failed to deliver real results. This search sparked an idea: to develop a truly natural, effective haircare range tailored to restoring and maintaining hair health. That idea became Sozo Hair Health, a line of high-performance, all-natural hair products manufactured on the Gold Coast and now loved by thousands across Australia and beyond. 'I didn't set out to start a business, ' Isabella explains. 'I just wanted to understand my own hair health and feel good again. But through that journey, I found a calling — to help others feel the same.' Sozo Hair Health products are crafted with ingredients that are not only natural but also scientifically supported. From aloe vera and hyaluronic acid to beetroot extract, finger lime, and hydrolysed quinoa, each product is designed to nourish the scalp and strengthen the hair, without compromising on performance. Other potent botanicals like green tea and lavender oil are carefully selected to soothe the scalp, reduce inflammation, support hair growth, and boost shine — naturally. 'I noticed the difference in my hair, after just one week using these products,' one impressed shopper wrote. 'My hair is so much softer and feels so much healthier after using this haircare,' another person added. 'My hair is loving this, so much shinier and amazing results,' a third reviewer commented. Best picks:
